Cybin wins new Buy from Guggenheim: potential to challenge J&J's Spravato cited

Stock Information for Cybin Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Cybin Inc.

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights
Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder
Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025
Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025
Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results
Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024
Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder
Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.